Ng recombinant vaccinia: implications for vaccine development. J Exp Med. 1992; 176:169?76. [PubMed: 1377222] 10. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus- certain cytotoxic T cell epitope in EBV nuclear antigen three (EBNA 3). J Exp Med. 1990; 171:345?49. [PubMed: 1688611] 11? Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008; 82:1448?457. A feasibility trial that demonstrated MFAP4 Protein Synonyms safety and immunogenicity of an EBV CD8+ T-cell peptide vaccine. When not practical for general use due to HLA restriction, it could possibly be studied in subjects whose HLA is nicely characterized, like pretransplant candidates. [PubMed: 18032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma sufferers. Cancer Res. 2013; 73:1676?688. A thoroughly made trial whose hypothesis is the fact that enhanced recognition of tumor cells via their expression of EBNA antigens EBNA-1 and LMP-2 will likely be therapeutic. Security, immunogenicity, along with a dose-response effect had been demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis–and what else? J Infect Dis. 2007; 196:1724?726. [PubMed: 18190249]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCurr Opin Virol. Author manuscript; offered in PMC 2015 June 01.BalfourPage14. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) towards the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61:1416?1420. [PubMed: 3033269] 15. Moss DJ, Pope JH. Assay of your infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972; 17:233?36. [PubMed: 4344316] 16. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 employing a speedy flow cytometry-based EBV neutralization assay. Virology. 2009; 391:249?56. [PubMed: 19584018] 17. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276:2030?033. [PubMed: 9197263] 18? Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Soluble rhesus lymphocryptovirus gp350 protects VEGF-C, Human (HEK293, His-Avi) against infection and reduces viral loads in animals that come to be infected with virus right after challenge. PLoS Pathog. 2011; 7:e1002308. A vital study in which rhesus macques had been protected from an EBV challenge infection just after receiving gp350 vaccine. [PubMed: 22028652] 19? Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic components related with acquisition and severity of major Epstein-Barr virus infection in university students. J Infect Dis. 2013; 207:80?8. A potential study demonstrating the substantial illness burden of major EBV infection in EBV-na e college freshmen. Such students are best subjects.

By mPEGS 1